Related Experiment Videos

Cost-effective management of heart failure

W W Parmley1

  • 1Department of Medicine, University of California, San Francisco, USA.

Clinical Cardiology
|March 1, 1996
PubMed

Insights

Heart failure impacts millions, costing billions annually, primarily due to hospitalizations. Angiotensin-converting enzyme (ACE) inhibitors are cost-effective treatments that reduce mortality and hospital stays.

Area of Science:

  • Cardiology
  • Health Economics

Background:

  • Heart failure affects over 2 million Americans, with 400,000 new diagnoses yearly.
  • The economic burden exceeds $10 billion annually, with hospitalization and nursing home care comprising the majority of costs.

Purpose of the Study:

  • To evaluate the cost-effectiveness of management strategies for heart failure.
  • To identify methods for reducing healthcare expenditures associated with heart failure.

Main Methods:

  • Review of current treatment protocols and healthcare spending data for heart failure.
  • Analysis of the impact of medications like angiotensin-converting enzyme (ACE) inhibitors on patient outcomes and costs.

Main Results:

  • Angiotensin-converting enzyme (ACE) inhibitors demonstrate significant cost-effectiveness by reducing mortality and hospitalization rates.
  • Hospitalization accounts for approximately 75% of heart failure-related costs.
  • Nursing home care represents nearly 20% of the total economic burden.

Conclusions:

  • Cost-effective heart failure management should prioritize preventing hospital admissions.
  • Optimizing the utilization of diagnostic tests can lead to additional healthcare savings.
  • ACE inhibitors are a vital, cost-effective tool in managing heart failure and reducing patient mortality.

Related Concept Videos